• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    1/22/24 12:31:11 PM ET
    $AQB
    $BBLG
    $BFRG
    $BIMI
    Meat/Poultry/Fish
    Consumer Staples
    Industrial Specialties
    Health Care
    Get the next $AQB alert in real time by email

    Gainers

    • Sagimet Biosciences (NASDAQ:SGMT) stock rose 103.5% to $13.88 during Monday's regular session. The company's market cap stands at $317.8 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 41.1% to $6.9. The market value of their outstanding shares is at $42.0 million.
    • Bone Biologics (NASDAQ:BBLG) shares increased by 32.3% to $4.3. The market value of their outstanding shares is at $2.2 million.
    • 60 Degrees (NASDAQ:SXTP) stock moved upwards by 26.19% to $0.79. The company's market cap stands at $4.5 million.
    • AquaBounty Techs (NASDAQ:AQB) stock rose 25.65% to $2.4. The company's market cap stands at $9.2 million.
    • BIMI Intl Medical (NASDAQ:BIMI) shares increased by 22.13% to $2.71. The company's market cap stands at $37.9 million.

    Losers

    • Virios Therapeutics (NASDAQ:VIRI) shares declined by 37.1% to $0.51 during Monday's regular session. The company's market cap stands at $9.8 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares declined by 24.04% to $0.4. The company's market cap stands at $6.3 million.
    • NexImmune (NASDAQ:NEXI) stock fell 20.11% to $5.59. The company's market cap stands at $5.9 million.
    • Synaptogenix (NASDAQ:SNPX) stock decreased by 19.52% to $0.19. The market value of their outstanding shares is at $3.9 million.
    • CNS Pharma (NASDAQ:CNSP) shares declined by 18.52% to $0.64. The market value of their outstanding shares is at $3.9 million.
    • Elicio Therapeutics (NASDAQ:ELTX) shares decreased by 17.95% to $3.85. The company's market cap stands at $36.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AQB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AQB
    $BBLG
    $BFRG
    $BIMI

    CompanyDatePrice TargetRatingAnalyst
    Elicio Therapeutics Inc.
    $ELTX
    3/10/2026$17.00Buy
    Rodman & Renshaw
    Sagimet Biosciences Inc.
    $SGMT
    2/3/2026$27.00Buy
    Guggenheim
    Sagimet Biosciences Inc.
    $SGMT
    1/28/2026$8.00Equal Weight
    Barclays
    Sagimet Biosciences Inc.
    $SGMT
    8/11/2025$28.00Outperform
    Wedbush
    Sagimet Biosciences Inc.
    $SGMT
    8/7/2025$29.00Buy
    H.C. Wainwright
    Sagimet Biosciences Inc.
    $SGMT
    7/24/2025$28.00Buy
    Canaccord Genuity
    Sagimet Biosciences Inc.
    $SGMT
    12/6/2024$30.00Outperform
    Oppenheimer
    Sagimet Biosciences Inc.
    $SGMT
    11/12/2024$12.00Buy
    UBS
    More analyst ratings

    $AQB
    $BBLG
    $BFRG
    $BIMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Elicio Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Elicio Therapeutics with a rating of Buy and set a new price target of $17.00

    3/10/26 8:40:26 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Sagimet Biosciences with a new price target

    Guggenheim initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $27.00

    2/3/26 7:59:13 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Sagimet Biosciences with a new price target

    Barclays initiated coverage of Sagimet Biosciences with a rating of Equal Weight and set a new price target of $8.00

    1/28/26 7:18:50 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $BBLG
    $BFRG
    $BIMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elicio Therapeutics Reports Inducement Grants

    BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on March 16, 2026, Elicio granted an aggregate of 1,600 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. The grant provides for the

    3/17/26 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Event-driven primary disease-free survival ("DFS") analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC") is anticipated in 1H 2026Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial The Company remains blinded to the Phase 2 AMPLIFY-7P trial clinical efficacy outcomes.Projected cash runway into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 DFS analysis in 1H 2026 BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of n

    3/12/26 4:05:00 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public Offering

    NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced that it acted as the exclusive placement agent in connection with a $3.5 million public offering by Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharmaceuticals" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. Shuttle Pharmaceuticals entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common s

    3/12/26 8:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $BBLG
    $BFRG
    $BIMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $12,204 worth of shares (12,963 units at $0.94), increasing direct ownership by 35% to 49,948 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/12/25 8:39:45 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Xu Cheryl bought $14,410 worth of shares (5,000 units at $2.88), increasing direct ownership by 46% to 15,816 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    6/5/25 8:53:09 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $BBLG
    $BFRG
    $BIMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Technology Officer Faulkner Eric

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:29 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Faulkner Eric

    3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:02 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer O'Loughlin Steve

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:01:43 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $BBLG
    $BFRG
    $BIMI
    SEC Filings

    View All

    SEC Form EFFECT filed by Elicio Therapeutics Inc.

    EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/17/26 12:15:11 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/16/26 9:19:42 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Elicio Therapeutics Inc.

    424B5 - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/16/26 9:18:38 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $BBLG
    $BFRG
    $BIMI
    Leadership Updates

    Live Leadership Updates

    View All

    Shuttle Pharmaceuticals Acquires AI Health Platform

    Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay

    11/21/25 9:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

    BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer ("CTO"). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms. He most recently served as Senior Vice President of Technical Development and Operations at Sail Biomedicines (a Flagship

    11/19/25 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

    Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK, June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ:SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine learning. BitGo, the leading infrastructure provider of digital asset solutions, has been selected to provide qualified custody, staking and trading services for Synaptogenix's TAO holdings. BitGo brings unmatched expertise and a proven track record to help Synaptogen

    6/24/25 9:15:00 AM ET
    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $BBLG
    $BFRG
    $BIMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 7:55:59 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Sagimet Biosciences Inc.

    SC 13G - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 5:05:18 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $BBLG
    $BFRG
    $BIMI
    Financials

    Live finance-specific insights

    View All

    AquaBounty Technologies Announces Third Quarter 2025 Financial Results

    Harvard, Massachusetts--(Newsfile Corp. - October 28, 2025) - AquaBounty Technologies, Inc. (NASDAQ:AQB) ("AquaBounty" or the "Company"), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company's financial results for the third quarter and nine months ended September 30, 2025.Third Quarter 2025 HighlightsNet loss for the quarter ended September 30, 2025 was $1.4 million compared to a net loss of $3.4 million for the quarter ended September 30, 2024. Included in the net loss for the current period was a non-cash asset impairment charge of $69 thousand related to certain equipment ("Ohio Equipment Assets") originally intend

    10/28/25 8:00:00 AM ET
    $AQB
    Meat/Poultry/Fish
    Consumer Staples

    AquaBounty Technologies Announces Second Quarter 2025 Financial Results

    Harvard, Massachusetts--(Newsfile Corp. - August 5, 2025) - AquaBounty Technologies, Inc. (NASDAQ:AQB) ("AquaBounty" or the "Company"), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company's financial results for the second quarter and six months ended June 30, 2025.Second Quarter 2025 HighlightsNet loss for the quarter ended June 30, 2025 was $3.4 million compared to a net loss of $50.5 million for the quarter ended June 30, 2024. Included in the net loss for the current period was a non-cash asset impairment charge of $1.2 million related to certain equipment ("Ohio Equipment Assets") originally intended for the Comp

    8/5/25 8:00:00 AM ET
    $AQB
    Meat/Poultry/Fish
    Consumer Staples

    AquaBounty Technologies Announces First Quarter 2025 Financial Results

    Harvard, Massachusetts--(Newsfile Corp. - May 15, 2025) - AquaBounty Technologies, Inc. (NASDAQ:AQB) ("AquaBounty" or the "Company"), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company's financial results for the first quarter ended March 31, 2025.First Quarter 2025 HighlightsNet income for the quarter ended March 31, 2025 was $401 thousand compared to a net loss of $11.3 million for the quarter ended March 31, 2024. Included in net income 2025 was a non-cash gain of $2.0 million on the forgiveness of an outstanding loan.On February 11, 2025, the Company completed the sale of certain equipment originally intended for

    5/15/25 10:57:00 AM ET
    $AQB
    Meat/Poultry/Fish
    Consumer Staples